QSS
LCTX icon

Quantitative Systematic Strategies’s Lineage Cell Therapeutics LCTX Stock Holding History

Quantitative Systematic Strategies’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,174
Closed -$46K – 784
2018
Q3 		$46K Buy
+22,174
New +$46.6K 0.01% 601
2018
Q2 		– Sell
-22,174
Closed -$52K – 704
2018
Q1 		$52K Buy
22,174
+1,600
+8% +$3.75K 0.01% 610
2017
Q4 		$39K Hold
20,574
– – 0.01% 526
2017
Q3 		$51K Hold
20,574
– – 0.01% 435
2017
Q2 		$57K Buy
+20,574
New +$57.5K 0.01% 429

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IA
IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Quantitative Systematic Strategies's LCTX Position: Q4 2018 in Review

Quantitative Systematic Strategies sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 22,174 shares — an estimated $46K sold.

Quantitative Systematic Strategies first reported a position in LCTX in Q2 2017 and held it in 5 quarters. The position peaked at $57K in Q2 2017. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

  • Quantitative Systematic Strategies reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 22,174 Lineage Cell Therapeutics shares in Q4 2018, an estimated $46K.
  • Quantitative Systematic Strategies first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 5 quarters.
  • Quantitative Systematic Strategies's Lineage Cell Therapeutics position peaked at $57K in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Quantitative Systematic Strategies's 13F filing for Q4 2018, filed 12 Feb 2019.